LAVAL, QC, April 24 /CNW/ - BioSyntech, Inc. ("BioSyntech" or "the
Company") (TSX: BSY), a biotechnology company developing novel products in
regenerative medicine, today announced that its abstract summarizing the
safety and effectiveness of BST-DermOn(TM) in promoting the healing of various
types of chronic wounds that have failed previous treatments, has been
selected for poster presentation at The 3rd Congress of the World Union of
Wound Healing Societies (WUWHS). The abstract is entitled "Interim Pilot Study
Results of a Chitosan-Based Hydrogel (BST-DermOn(TM)) in the Treatment of
Chronic Wounds". Results of this open, non-controlled study will be presented
in a poster authored by Dr. Gary Sibbald, a world-renowned dermatologist and
recognized leader in the field of wound care, and the Principal Investigator
of the Company's BST-DermOn(TM) pivotal trial. The WUWHS Congress will be held
in Toronto, Ontario, from June 4 - 8, 2008.
